AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03712254
Drug: Fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
Trial: NCT03242993
Drug: [18F]-AzaFol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
Trial: NCT03242993
Drug: folarell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection
Trial: NCT03291418
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of gastrointestinal effects
Trial: NCT01283373
Drug: DSTP3086S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSTP3086S administered intravenously
Trial: NCT01283373
Drug: DSTP3086S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating intravenous dose
Trial: NCT00349271
Drug: Standart therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drug with clinical evidence of benefical effect in Chagas disease
Trial: NCT03462290
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
Trial: NCT00378079
Drug: Counseling + Transfer
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling only in prison, with opportunity to enter methadone maintenance upon release
Trial: NCT03905447
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care antifungal medication
Trial: NCT00006044
Drug: therapeutic testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03091777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive arm of the study
Trial: NCT02268019
Drug: epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04136756
Drug: NKTR-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
Trial: NCT04136756
Drug: NKTR-255 Q21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
Trial: NCT01379079
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin intake at bedtime
Trial: NCT01379079
Drug: Acetylsalicylic acid lysinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin intake on awakening
Trial: NCT02220998
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Trial: NCT02220998
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablet administered orally once daily
Trial: NCT01336608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00089674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Trial: NCT02763566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00515385
Drug: MGAWN1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Trial: NCT00515385
Drug: MGAWN1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose
Trial: NCT01957631
Drug: Corticosteroid injection (Bupivacaine and Depo Medrol)
RxNorm normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
Trial: NCT00201734
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
Trial: NCT00822263
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-oxidant in a pill format
Trial: NCT02063386
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose 15 mg of \[14C\]AZD1722
Trial: NCT01776619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 day repeated BID doses
Trial: NCT01571024
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 40 mg, orally, once daily.
Trial: NCT01571024
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
Trial: NCT00545181
Drug: Vaginal acidifying gel (RepHresh)
RxNorm normalized name: Rephresh Pro-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of vaginal acidifying gel into vagina to restore normal vaginal pH.
Trial: NCT01159119
Drug: EUR-1066-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
Trial: NCT01159119
Drug: EUR-1066-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
Trial: NCT02820714
Drug: BLI801 Laxative
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI801 Laxative
Trial: NCT03395574
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug will be given after 30 minutes as placebo in control group
Trial: NCT00739596
Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
Trial: NCT01289431
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Trial: NCT02305277
Drug: BIA 9-1067 (clinical micronized, CM)
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02855632
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
Trial: NCT02855632
Drug: hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Trial: NCT02054468
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (0.1-0.2µg/kg/min)
Trial: NCT00805233
Drug: combination ranibizumab + bromfenac
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
Trial: NCT02770443
Drug: withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: withdrawal of beta blocker and ACE inhibitors
Trial: NCT02770443
Drug: standard of CARE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
Trial: NCT02718976
Drug: Lidocaine-epinephrine added gadoterate meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
Trial: NCT01135108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV Infusion
Trial: NCT01120223
Drug: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT03216954
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo capsules
Trial: NCT00829439
Drug: Levodopa/Carbidopa (4:1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Trial: NCT00252304
Drug: Zinc (zinc sulphate)
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Trial: NCT00252304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00842088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule. Administered orally once a day on dosing days.
Trial: NCT00842088
Drug: HQK-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
Trial: NCT01676363
Drug: Diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label diflunisal 500 mg twice daily for 4 weeks
Trial: NCT01591850
Drug: RO5093151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT00298025
Drug: Cetrotide®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
Trial: NCT00298025
Drug: Antagon ™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
Trial: NCT01322308
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet taken once a day
Trial: NCT02374047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03624530
Drug: Tyrosine kinase inhibitor (TKIs)
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
Trial: NCT00967928
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
Trial: NCT04048811
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
Trial: NCT00352716
Drug: Smecta (Diosmectite), duration of treatment - 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01444677
Drug: MB12066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB12066 300mg
Trial: NCT01444677
Drug: MB12066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB12066 400mg
Trial: NCT01444677
Drug: MB12066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB12066 100mg
Trial: NCT01444677
Drug: MB12066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB12066 200mg
Trial: NCT01444677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
Trial: NCT00812305
Drug: SKY0402 300mg in healthy patients
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
Trial: NCT01540682
Drug: MLN8237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
Trial: NCT03140085
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application
Trial: NCT01575288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100g maltose 1/day
Trial: NCT01418352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole matching-placebo once-weekly for 8 weeks.
Trial: NCT03236493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as tablet
Trial: NCT03676764
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
Trial: NCT03676764
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
Trial: NCT00819546
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
Trial: NCT00819546
Drug: PKC412
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
Trial: NCT04495894
Drug: Preoperative Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
Trial: NCT00947245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Single Dose, One day
Trial: NCT00947245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Every 12 hours, 14 days
Trial: NCT00947245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Once Daily, 14 days
Trial: NCT00947245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, Every 12 hours or once daily, 14 days
Trial: NCT03603431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo
Trial: NCT03603431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Placebo
Trial: NCT00962182
Drug: STAN1
RxNorm normalized name: Stan Gard 0.4 % Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 capsules/day at meals
Trial: NCT00962182
Drug: Placebo enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 capsules/day at meals
Trial: NCT00962182
Drug: STAN1+gluten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 capsules/day at meals plus 500 mg gluten b.i.d
Trial: NCT00527397
Drug: CP-464,005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
Trial: NCT00527397
Drug: CP-464,005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
Trial: NCT00367770
Drug: Tracleer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to 125 mg b.i.d. of Tracleer.
Trial: NCT01108978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Trial: NCT01108978
Drug: Dehypotin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
Trial: NCT02480712
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
Trial: NCT00862888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral solution
Trial: NCT00862888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for tablet
Trial: NCT04619069
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Hormone Therapy per physician discretion (Min. 8 months)
Trial: NCT04336488
Drug: Kenacort A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of both drugs 3 times daily for 3 weeks as an active control
Trial: NCT00479401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03296553
Drug: Antiretroviral Combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard antiretroviral treatment as recommended
Trial: NCT02023866
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine Bitartrate Delayed-release capsules
Trial: NCT00298025
Drug: Recombinant Human Choriogonadotropin (r-hCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
Trial: NCT02125643
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00095680
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 30-mg capsules three times daily
Trial: NCT05535595
Drug: genotyping and selection of renin-angiotensin system blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of perindopril or candesartan was chosen based on genotyping results on two NELL1 variants.~* perindopril 4 mg/d after genotyping~* candesartan 8 mg/d after genotyping
Trial: NCT00558519
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00558519
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00558519
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00558519
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01755611
Drug: Minocycline 100mg
RxNorm normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product
Trial: NCT01755611
Drug: Minocycline 100mg
RxNorm normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference product